ArticlePharmaceutics2025
Human OAT1, OAT3, OAT4 and OATP1A2 Facilitate the Renal Accumulation of Ochratoxin A.
Anish Mahadeo, Yik Pui Tsang, Angela R Zheng, Sydney Arnzen, Acilegna G Rodriguez, Mark S Warren, Zsuzsanna Gáborik, Edward J Kelly
Abstract read
In one paragraphArticle in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Anish MahadeoDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA.
Yik Pui TsangDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA.
Angela R ZhengDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA.ORCID 0009-0004-9560-6028 Sydney ArnzenDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA.ORCID 0009-0002-6190-6415 Acilegna G RodriguezBioIVT, 3010 Kenneth St., Santa Clara, CA 95054, USA.
Mark S WarrenBioIVT, 3010 Kenneth St., Santa Clara, CA 95054, USA.
Zsuzsanna GáborikSOLVO Biotechnology, Charles River Laboratories Hungary, 1117 Budapest, Hungary.
Edward J KellyDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-6534-9313 Funding
Translational center for kidney microphysiological systems to improve drug safety and efficacyU2CTR004867 · NCATS · UNIVERSITY OF WASHINGTON · PI Benjamin Solomon Freedman, Jonathan Himmelfarb · 2024 to 2026
$4.8MA Microphysiological System for Kidney Disease Modeling and Drug Efficacy TestingUG3TR002158 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2017 to 2018
$2.9MCKDu and Ochratoxin-A: risk assessment studies in a microphysiological systemR21ES031359 · NIEHS · UNIVERSITY OF WASHINGTON · PI KELLY, EDWARD J · 2020 to 2021
$404kNCATS NIH HHS U2C TR004867NCATS NIH HHS UG3TR002158NIEHS NIH HHS R21 ES031359NIEHS NIH HHS R21ES031359University of Washington School of Pharmacy Ji-Ping Wang and William E. Bradley awards
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
chronic kidney disease of unknown etiologynephrotoxicityochratoxin Arenal proximal tubulerenal transporterstransporter-mediated disposition
Identifiers
PMID41304811
PMCPMC12655426
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390